Comparative in-vitro activity of Sch 29482, a new penem antibiotic

Publisher Website
Google Scholar
Abstract
We examined the activity of Sch 29482 (SCH) in vitro using an agar dilution technique against 497 clinical bacterial isolates. Ampicillin, mezlocillin, piperacillin, cefazolin, cefaperazone, cefotaxime, ceftazidime, moxalactam and gentamicin were used for comparison. SCH exhibited activity against all species tested, excepting Pseudomonas aeruginosa and Pseudomonas species . Unlike many newer β lactams, SCH was highly active against Gram positive species. It was consistently active against enterobacterial species, with MIC 50 and MIC 90 being usually closely similar, as were results with 2 inoculum sizes (10 4 and 10 6 cfu). This, coupled with the activity of SCH against strains resistant to many other antibacterials, and against transconjugants prepared in vitro harbouring R-plasmids coding for β -lactamases, suggested high stability to β -lactamases. SCH was the most active compound tested against Bacteroides fragilis . In tests of combined bacteristatic action with gentamicin synergy was seen with Proteus retigeri and gentamicin-resistant strains of Escherichia coli and Ps. aeruginosa . SCH had bactericidal action similar in its rate to that of ampicillin against sensitive strains of E. coli, Kiebsiella pnewnoniae, Proteus mirabilis, Staphylococcus aureus and Streptococcus faecalis . We concluded that SCH is a highly promising agent with broad spectrum of activity making it potentially suitable as monotherapy for patients with sepsis of undetermined bacterial aetiology, particularly if Bact. fragilis was a possible pathogen.

This publication has 2 references indexed in Scilit: